# A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens

> **NCT03412565** · PHASE2 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 265 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Daratumumab
- **DRUG:** Bortezomib
- **DRUG:** Lenalidomide
- **DRUG:** Dexamethasone
- **DRUG:** Melphalan
- **DRUG:** Prednisone
- **DRUG:** Carfilzomib

## Key facts

- **NCT ID:** NCT03412565
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-04-26
- **Primary completion:** 2020-08-12
- **Final completion:** 2024-04-18
- **Target enrollment:** 265 (ACTUAL)
- **Last updated:** 2025-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03412565

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03412565, "A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03412565. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*